Paper
A condition family can be important not only because many studies are missing results, but because the backlog stays unresolved for a very long time.
Which condition families hold the deepest overdue debt once unresolved years beyond the two-year mark are added up rather than reduced to missing-results rate? We analysed 249,507 eligible older closed interventional studies from the March 29, 2026 full-registry snapshot using one condition-family label per study. We summed overdue years beyond the two-year mark across condition families and compared debt stock with missing-results counts and mean unresolved age. The broad OTHER bucket carried the largest condition-family overdue debt at 289,823 unresolved years, while Oncology was the largest named family at 255,229 and Cardiovascular followed at 154,672. Metabolic and healthy-volunteer portfolios also carried very large overdue debt, while oncology had the heaviest named-family mean unresolved age at 9.0 years. Condition debt mixes broad diffuse registry stock with large named disease portfolios that stay unresolved for years after the reporting window closes. Condition families are keyword-derived registry groupings, so the debt tables describe therapeutic portfolios rather than disease ontologies.